Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.

Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10(1):16425. https://doi.org/10.1038/s41598-020-73525-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malik NK, May KS, Chandrasekhar R, Wee W, Flaherty L, Iyer R, et al. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol. 2012;3(4):326–34. https://doi.org/10.3978/j.issn.2078-6891.2012.029.

Article  PubMed  PubMed Central  Google Scholar 

Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of pancreatic surgery (ISGPS). Surgery. 2014;155(6):977–88. https://doi.org/10.1016/j.surg.2014.02.001.

Article  PubMed  Google Scholar 

Pajewska M, Partyka O, Czerw A, Deptala A, Cipora E, Gaska I, et al. Management of metastatic pancreatic Cancer-comparison of global guidelines over the last 5 years. Cancers (Basel). 2023;15(17). https://doi.org/10.3390/cancers15174400.

Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193–9. https://doi.org/10.7150/ijms.3635.

Article  PubMed  PubMed Central  Google Scholar 

Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in patients with locally Advanced Pancreatic Cancer Controlled after 4 months of Gemcitabine with or without Erlotinib: the LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844–53. https://doi.org/10.1001/jama.2016.4324.

Article  CAS  PubMed  Google Scholar 

Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592–9. https://doi.org/10.1093/annonc/mdn281.

Article  CAS  PubMed  Google Scholar 

Wang Z, Ren ZG, Ma NY, Zhao JD, Zhang Z, Ma XJ, et al. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis. Radiat Oncol. 2015;10:14. https://doi.org/10.1186/s13014-014-0312-5.

Article  PubMed  PubMed Central  Google Scholar 

Loehrer PJ, Sr., Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105–12. https://doi.org/10.1200/jco.2011.34.8904.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tchelebi LT, Lehrer EJ, Trifiletti DM, Sharma NK, Gusani NJ, Crane CH, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis. Cancer. 2020;126(10):2120–31. https://doi.org/10.1002/cncr.32756.

Article  CAS  PubMed  Google Scholar 

Sherman MH, Beatty GL. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. Annu Rev Pathol. 2023;18:123–48. https://doi.org/10.1146/annurev-pathmechdis-031621-024600.

Article  CAS  PubMed  Google Scholar 

Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y, et al. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2017;1868(1):69–92. https://doi.org/10.1016/j.bbcan.2017.02.003.

Article  CAS  PubMed  Google Scholar 

Sun X, Wu L, Du L, Xu W, Han M. Targeting the organelle for radiosensitization in cancer radiotherapy. Asian J Pharm Sci. 2024;19(2):100903. https://doi.org/10.1016/j.ajps.2024.100903.

Article  PubMed  PubMed Central  Google Scholar 

Suwa T, Kobayashi M, Nam JM, Harada H. Tumor microenvironment and radioresistance. Exp Mol Med. 2021;53(6):1029–35. https://doi.org/10.1038/s12276-021-00640-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. https://doi.org/10.1186/1471-2105-9-559.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. https://doi.org/10.1093/nar/gkv007.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blum A, Wang P, Zenklusen JC, SnapShot. TCGA-Analyzed tumors. Cell. 2018;173(2):530. https://doi.org/10.1016/j.cell.2018.03.059.

Article  CAS  PubMed  Google Scholar 

Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71. https://doi.org/10.1093/nar/gkv1507.

Article  CAS  PubMed  Google Scholar 

Davis S, Meltzer PS. GEOquery: a bridge between the Gene expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007;23(14):1846–7. https://doi.org/10.1093/bioinformatics/btm254.

Article  CAS  PubMed  Google Scholar 

McCarthy DJ, Smyth GK. Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics. 2009;25(6):765–71. https://doi.org/10.1093/bioinformatics/btp053.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7. https://doi.org/10.1089/omi.2011.0118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385–95. https://doi.org/10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3.

Article  CAS  PubMed  Google Scholar 

Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor infiltrating Immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–59. https://doi.org/10.1007/978-1-4939-7493-1_12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8. https://doi.org/10.1038/s41591-018-0136-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–62. https://doi.org/10.1016/j.celrep.2016.12.019.

Article  CAS  PubMed  Google Scholar 

Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6). https://doi.org/10.1093/bib/bbab260.

Wang D, Luo H, Chen Y, Ou Y, Dong M, Chen J, et al. 14-3-3sigma downregulation sensitizes pancreatic cancer to carbon ions by suppressing the homologous recombination repair pathway. Aging. 2024;16(11):9727–52. https://doi.org/10.18632/aging.205896.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karamitopoulou E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J